<DOC>
	<DOCNO>NCT01007448</DOCNO>
	<brief_summary>This multicenter , randomize , open-label , Phase IV study ass efficacy , tolerability safety two initial dose level bexarotene capsule patient refractory cutaneous T-cell lymphoma ( CTCL ) .</brief_summary>
	<brief_title>Study Evaluating Two Dose Levels Targretin Capsules Patients With Refractory Cutaneous T-cell Lymphoma ( CTCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>1 . A clinical diagnosis cutaneous Tcell lymphoma ( CTCL ) without central nervous system ( CNS ) involvement , confirm biopsy histologically consistent CTCL diagnosis dermatopathologist . 2 . Refractory least one systemic therapy CTCL . ( Refractory define resistance therapy due either lack response least 50 % improvement progression disease still therapy initial response ) . 3 . Systemic therapy CTCL indicate . 4 . A Karnofsky performance score ≥ 60 % . 5 . Age ≥18 year . 6 . Females childbearing potential must negative serum beta human chorionic gonadotropin ( ßhCG ) sensitivity least 50 mIU/L within seven day prior initiation treatment . Females childbearing potential must use simultaneously two highly effective method contraception ( strongly recommend one two form contraception nonhormonal condom plus spermicide , condom plus diaphragm spermicide , vasectomized partner ) use intrauterine device must sexually abstinent least four week prior least one menstrual cycle prior ( whichever longer ) negative pregnancy test entry study . Sexual abstinence effective contraception must use least one month prior initiation therapy , therapy , least one month follow discontinuation therapy . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 7 . Male patient female partner childbearing potential must agree sexual abstinence practice two reliable form effective contraception use simultaneously ( strongly recommend one two form contraception nonhormonal condom plus spermicide , condom plus diaphragm spermicide , partner tubal ligation ) partner may use intrauterine device , entire period Targretin capsule treatment least one month treatment discontinue . Male patient female sexual partner pregnant , possibly pregnant could become pregnant study must agree use condom sexual intercourse entire period Targretin capsule treatment least one month last dose Targretin capsule . 8 . Must willing able give inform consent , complete understand , either oral write , study procedure assessment . 9 . Patient must suitable participation study investigator 's opinion . 10 . Fasting serum triglyceride within normal limit ( &lt; 150 mg/dL ) prior study entry . 11 . Adequate renal function evidence serum creatinine ≤ 2.0 mg/dL calculate creatinine clearance ≥ 40 mL/min per Cockroft Gault formula . 12 . Adequate hepatic function characterize aspartate aminotransferase ( SGOT [ AST ] ) , alanine aminotransferase ( SGPT [ ALT ] ) , serum bilirubin &lt; 2.5 time upper limit normal . 13 . Adequate bone marrow function evidence hemoglobin ≥ 8 g/dL , absolute neutrophil count ( ANC ) ≥ 1,000/mm3 , platelet ≥ 50,000/mm3 . Exclusion Criteria 1 . Cutaneous Tcell lymphoma involve central nervous system . 2 . Patients know Human Immunodeficiency Virus ( HIV ) infection active Hepatitis B Virus ( HBV ) Hepatitis C Virus ( HCV ) infection ( HBV/ HCV HIV test require purpose study ) 3 . Participation investigational drug study within thirty ( 30 ) day entry study . 4 . Within five ( 5 ) year onset menopause . 5 . Received systemic corticosteroid within six ( 6 ) month entry study . 6 . Known hypersensitivity bexarotene component Targretin capsule . 7 . Pregnancy , intent become pregnant , breastfeed . 8 . Received gemfibrozil within one ( 1 ) day start study . 9 . Prior therapy treatment CTCL : 1 . PUVA UVB therapy within three ( 3 ) week study entry 2 . EBT photopheresis within three ( 3 ) week study entry 3 . Topical retinoids , nitrogen mustard , BCNU , imiquimod , etc . within two ( 2 ) week study entry If antipruritic medication avoid , antihistamine antipruritic agent must administer use stable dose regimen least one ( 1 ) week prior initiation study drug treatment throughout study , unless determine discontinuation reduction dose indicate . Prior enrollment patient take systemic dermatologicallyapplied antihistamine antipruritic agent , investigator must contact Eisai discuss need agent . Mineral oil , baby oil , simple moisturize lotion may use emollient . Low mid potency topical corticosteroid allow ONLY patient erythroderma ( stage III/IV CTCL ) use stable dose regimen least four ( 4 ) week prior study entry . High potency topical corticosteroid tar bath NOT permit . NOTE : Prior enrollment patient take systemic dermatologicallyapplied antihistamine antipruritic agent , investigator must contact Sponsor discuss need agent . 4 . Anticancer therapy kind ( e.g. , methotrexate , cyclophosphamide , vorinostat , romidepsin , interferon , etc ) within thirty ( 30 ) day entry study . Patient must recover sign toxicity prior entry study . 5 . Oral retinoid therapy indication within three ( 3 ) month study entry 6 . Systemic therapy Vitamin A dose great 15,000 IU ( 5,000 mcg ) per day ( equivalent approximately three time RDA ) within thirty ( 30 ) day entry study ) . 10 . Systemic antibiotic therapy within two ( 2 ) week entry study . ( Patients infection require antibiotic likely require antibiotic appropriately treat course antibiotic terminate least two week prior entry , indicate , chronic suppressive prophylactic dose antibiotic stabilize least two ( 2 ) week prior entry . Patients require initiation change antibiotic therapy study consider violation protocol ) . 11 . History pancreatitis significant risk factor develop pancreatitis ( e.g. , prior pancreatitis , uncontrolled hyperlipidemia , excessive alcohol consumption , uncontrolled diabetes mellitus , biliary tract disease , medication know increase triglyceride level associate pancreatic toxicity ) . 12 . Unwillingness inability minimize exposure sunlight artificial ultraviolet light receive Targretin capsule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>CTCL</keyword>
	<keyword>bexarotene</keyword>
	<keyword>Targretin</keyword>
	<keyword>Refractory Cutaneous T-cell Lymphoma</keyword>
	<keyword>cutaneous T-cell Lymphoma</keyword>
	<keyword>MF</keyword>
	<keyword>Mycoses fungoides</keyword>
</DOC>